News Release
Chill Brands Group gives itself "really good growth capital" with latest fundraise
Chill Brands Group PLC
Chill Brands Group PLC (LSE:CHLL, OTCQB:CHBRF) CEO Callum Sommerton speaks to Proactive after announcing a £2.6mln fundraise that he says provides the company with "really good growth capital". Sommerton also talks about the company's expansion into nicotine-free vaping, something he sees as serious growth opportunity in a changing market. Contact Details UK Editorial +44 20 7989 0813 uk@proactiveinvestors.com
April 06, 2023 09:55 AM Eastern Daylight Time
Video
News Release
Destiny Pharma upbeat on prospects for C. Difficile treatment
Destiny Pharma PLC
Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief scientific officer Bill Love speaks to Proactive after results from a study into its C. Difficile treatment platform NTCD-M3 were published in the Microbiology Spectrum journal. Love explains what makes the platform so promising from Destiny's point of view, before going on to reveal more about the plans for bringing NTCD-M3 to the market. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
April 06, 2023 09:53 AM Eastern Daylight Time
Video
News Release
Futura Medical "confident of getting FDA approval this quarter"
Futura Medical PLC
Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Proactive following the release of full year results for 2022. Barder says that despite losses, revenues "are now rapidly coming over the horizon" and he suggests "the last two years have been very very good for us". He adds that he's "confident of getting FDA approval for MED3000 this quarter" Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
April 06, 2023 06:12 AM Eastern Daylight Time
Video
News Release
Faron Pharmaceuticals moving "into next phase" with new CFO
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief financial officer James O'Brien speaks to Proactive on his second day in the new role. O'Brien reveals more about what he believes he can bring to Faron, highlighting his experience in the US capital markets. He adds that Faron is now moving "into [its} next phase of growth." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
April 06, 2023 05:27 AM Eastern Daylight Time
Video
News Release
MGC Pharmaceuticals' focus "will not change" despite psilocybin news
MGC Pharmaceuticals Ltd
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive after announcing that the company has been granted permission by the Slovenian government to conduct research into psilocybin, a naturally occurring psychedelic compound found in certain types of mushrooms. The company will work in partnership with other pharmaceutical companies to determine the best potential use for psilocybin. Clements says that "the focus of MGC will not change" despite the news, adding that it is fully committed to its current pipeline of products. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
April 06, 2023 05:14 AM Eastern Daylight Time
Video
News Release
Xeris Biopharma enters research collaboration with Regeneron Pharmaceuticals to advance XeriJect
Xeris Biopharma Holdings
Xeris Biopharma chairman and CEO Paul Edick joins Proactive's Natalie Stoberman to share details behind its research evaluation collaboration with Regeneron Pharmaceuticals for further XeriJect development. Edick says the agreement will see Xeris using its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small volume subcutaneous injections of two undisclosed monoclonal antibodies developed by Regeneron. Xeris will receive an upfront payment and potential milestone payments for preclinical achievements. Regeneron will have an option to commercially license the Xeris technology for such molecules and nominate additional molecules for reformulation and potential commercialization. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com
April 05, 2023 01:18 PM Eastern Daylight Time
Video
News Release
HealthLynked discusses year-end financials and MedOfficeDirect prospects in development
HealthLynked
HealthLynked chairman and CEO Dr Michael Dent and chief financial officer George O'Leary join Proactive's Natalie Stoberman to share highlights from the company's fourth-quarter and full-year 2022 financial results. HealthLynked reported revenue of $5.86 million, a 10% decrease compared to $6.50 million in 2021. Dent says the decline is primarily attributed to decreases in patient service revenue at the Naples Women’s Center and Bridging the Gap facilities, as well as lower product revenue from MedOfficeDirect. However, the company has reported that the decrease was partially offset by revenue increases at its Naples Center for Functional Medicine facility and revenue from the newly-acquired Aesthetics Enhancements Unlimited practice. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com
April 05, 2023 01:13 PM Eastern Daylight Time
Video
News Release
Algernon NeuroScience reports successful second cohort dosing in DMT clinical study
Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon Neuroscience has completed dosing of the second cohort in the Phase 1 clinical study of DMT. Moreau tells Proactive the study is to identify the safety and tolerability of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours which has never been studied clinically. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com
April 05, 2023 01:03 PM Eastern Daylight Time
Video
News Release
BioHarvest Sciences announces launch of “Real Stories” media campaign for VINIA red grape supplement
BioHarvest Sciences Inc.
BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share news the company will be launching a major media campaign to support its flagship supplement VINIA in the United States. Sobel tells Proactive the campaign will use real VINIA users telling their ‘Real Stories” on television and social media. The science behind the product will also be highlighted. BioHarvest has set its 2023 guidance with plans to increase global VINIA sales to over US$17 million. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com
April 05, 2023 12:25 PM Eastern Daylight Time
Video
